BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

430 related articles for article (PubMed ID: 26367725)

  • 1. Lack of association between CXCL9 and CXCL10 gene polymorphisms and the outcome of rheumatoid arthritis treatment with methotrexate.
    Kotrych D; Dziedziejko V; Safranow K; Pawlik A
    Eur Rev Med Pharmacol Sci; 2015 Aug; 19(16):3037-40. PubMed ID: 26367725
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of dihydrofolate reductase (DHFR) -317AA genotype with poor response to methotrexate in patients with rheumatoid arthritis.
    Milic V; Jekic B; Lukovic L; Bunjevacki V; Milasin J; Novakovic I; Damnjanovic T; Popovic B; Maksimovic N; Damjanov N; Radunovic G; Pejnovic N; Krajinovic M
    Clin Exp Rheumatol; 2012; 30(2):178-83. PubMed ID: 22324981
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of allograft inflammatory factor-1 gene polymorphisms on rheumatoid arthritis treatment with methotrexate.
    Pawlik A; Herczynska MM; Dziedziejko V; Malinowski D; Kurzawski M; Drozdzik M; Gawronska-Szklarz B
    Postepy Hig Med Dosw (Online); 2013 Jul; 67():637-42. PubMed ID: 24018427
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CXCL9 and CXCL10 gene polymorphisms in patients with rheumatoid arthritis.
    Kotrych D; Dziedziejko V; Safranow K; Drozdzik M; Pawlik A
    Rheumatol Int; 2015 Aug; 35(8):1319-23. PubMed ID: 25702175
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reduced folate carrier-1 80G>A polymorphism affects methotrexate treatment outcome in rheumatoid arthritis.
    Drozdzik M; Rudas T; Pawlik A; Gornik W; Kurzawski M; Herczynska M
    Pharmacogenomics J; 2007 Dec; 7(6):404-7. PubMed ID: 17325736
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of ESR1 and ESR2 gene polymorphisms on rheumatoid arthritis treatment with methotrexate.
    Pawlik A; Dziedziejko V; Kurzawski M; Safranow K; Kotrych D; Bohatyrewicz A
    Pharmacol Rep; 2012; 64(1):185-90. PubMed ID: 22580535
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase II, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of MDX-1100, a fully human anti-CXCL10 monoclonal antibody, in combination with methotrexate in patients with rheumatoid arthritis.
    Yellin M; Paliienko I; Balanescu A; Ter-Vartanian S; Tseluyko V; Xu LA; Tao X; Cardarelli PM; Leblanc H; Nichol G; Ancuta C; Chirieac R; Luo A
    Arthritis Rheum; 2012 Jun; 64(6):1730-9. PubMed ID: 22147649
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Methylenetetrahydrofolate reductase polymorphisms and methotrexate: no association with response to therapy nor with drug-related adverse events in an Italian population of rheumatic patients.
    Taraborelli M; Andreoli L; Archetti S; Ferrari M; Cattaneo R; Tincani A
    Clin Exp Rheumatol; 2009; 27(3):499-502. PubMed ID: 19604445
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ABCB1 C3435T polymorphism influences methotrexate sensitivity in rheumatoid arthritis patients.
    Takatori R; Takahashi KA; Tokunaga D; Hojo T; Fujioka M; Asano T; Hirata T; Kawahito Y; Satomi Y; Nishino H; Tanaka T; Hirota Y; Kubo T
    Clin Exp Rheumatol; 2006; 24(5):546-54. PubMed ID: 17181924
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The association between reduced folate carrier-1 gene 80G/A polymorphism and methotrexate efficacy or methotrexate related-toxicity in rheumatoid arthritis: A meta-analysis.
    Li X; Hu M; Li W; Gu L; Chen M; Ding H; Vanarsa K; Du Y
    Int Immunopharmacol; 2016 Sep; 38():8-15. PubMed ID: 27233001
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of key TYMS polymorphisms on methotrexate therapeutic outcome in portuguese rheumatoid arthritis patients.
    Lima A; Seabra V; Bernardes M; Azevedo R; Sousa H; Medeiros R
    PLoS One; 2014; 9(10):e108165. PubMed ID: 25279663
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The impact of C677T and A1298C MTHFR polymorphisms on methotrexate therapeutic response in East Bohemian region rheumatoid arthritis patients.
    Soukup T; Dosedel M; Pavek P; Nekvindova J; Barvik I; Bubancova I; Bradna P; Kubena AA; Carazo AF; Veleta T; Vlcek J
    Rheumatol Int; 2015 Jul; 35(7):1149-61. PubMed ID: 25618758
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of the ATIC 347 C/G polymorphism with responsiveness to and toxicity of methotrexate in rheumatoid arthritis: a meta-analysis.
    Lee YH; Bae SC
    Rheumatol Int; 2016 Nov; 36(11):1591-1599. PubMed ID: 27379764
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness, tolerability, and safety of subcutaneous methotrexate in early rheumatoid arthritis: A retrospective analysis of real-world data from the St. Gallen cohort.
    Müller RB; von Kempis J; Haile SR; Schiff MH
    Semin Arthritis Rheum; 2015 Aug; 45(1):28-34. PubMed ID: 25895697
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetic Determinants of Methotrexate Toxicity in Tunisian Patients with Rheumatoid Arthritis: A Study of Polymorphisms Involved in the MTX Metabolic Pathway.
    Chaabane S; Marzouk S; Akrout R; Ben Hamad M; Achour Y; Rebai A; Keskes L; Fourati H; Bahloul Z; Maalej A
    Eur J Drug Metab Pharmacokinet; 2016 Aug; 41(4):385-93. PubMed ID: 26077125
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 2756GG genotype of methionine synthase reductase gene is more prevalent in rheumatoid arthritis patients treated with methotrexate and is associated with methotrexate-induced nodulosis.
    Berkun Y; Abou Atta I; Rubinow A; Orbach H; Levartovsky D; Aamar S; Arbel O; Dresner-Pollak R; Friedman G; Ben-Yehuda A
    J Rheumatol; 2007 Aug; 34(8):1664-9. PubMed ID: 17611986
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Functional polymorphisms and methotrexate treatment outcome in recent-onset rheumatoid arthritis.
    Kooloos WM; Wessels JA; van der Straaten T; Allaart CF; Huizinga TW; Guchelaar HJ
    Pharmacogenomics; 2010 Feb; 11(2):163-75. PubMed ID: 20136356
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Polymorphisms in the thymidylate synthase and methylenetetrahydrofolate reductase genes and sensitivity to the low-dose methotrexate therapy in patients with rheumatoid arthritis.
    Kumagai K; Hiyama K; Oyama T; Maeda H; Kohno N
    Int J Mol Med; 2003 May; 11(5):593-600. PubMed ID: 12684695
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reduced folate carrier-1 80G > A gene polymorphism is not associated with methotrexate treatment response in South Indian Tamils with rheumatoid arthritis.
    Muralidharan N; Mariaselvam CM; Mithun CB; Negi VS
    Clin Rheumatol; 2016 Apr; 35(4):879-85. PubMed ID: 25771854
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of C35T polymorphism in dihydrofolate reductase gene with toxicity of methotrexate in rheumatoid arthritis patients.
    Vejnović D; Milić V; Popović B; Damnjanović T; Maksimović N; Bunjevački V; Krajinović M; Novaković I; Damjanov N; Jekić B
    Expert Opin Drug Metab Toxicol; 2019 Mar; 15(3):253-257. PubMed ID: 30583708
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.